Ocera Therapeutics, Inc.
Apr 22, 2015

Ocera Therapeutics to Report Pipeline Progress and First Quarter 2015 Financial Results

PALO ALTO, Calif., April 22, 2015 (GLOBE NEWSWIRE) -- Ocera Therapeutics, Inc. (Nasdaq:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that it will release its first quarter 2015 financial results on Thursday, April 30, 2015 at approximately 8:00 a.m. Eastern Time. In conjunction with this announcement, Ocera will host a conference call and webcast on Thursday, April 30, 2015 at 10:00 a.m. Eastern Time to both review the financial results and provide updates on its clinical development program.

To access the conference call via phone, dial 877-317-6789. International callers may access the live call by dialing 412-317-6789. The reference name to enter the call is Ocera Therapeutics, Inc. A live webcast of the conference call will also be available online from the investor relations events page of the Company's corporate website at www.ocerainc.com.

A replay of the webcast will be available on www.ocerainc.com for three months and a replay of the conference call may be accessed on Thursday, April 30, 2015 after 8:00 p.m. ET, via phone at 877-344-7529 for domestic callers, or 412-317-0088 for international callers. The reference number to enter the replay of the call is 10064831.

About Ocera

Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.

CONTACT: Susan Sharpe

         Ocera Therapeutics, Inc.

         contact@ocerainc.com

         919-328-1109